country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-182971

Copy Link Print Information

PROTAC EV-A71 Degrader-1

PROTAC EV-A71 Degrader-1 is a PROTAC degrader targeting EV-A71 3D polymerase, with broad-spectrum activity against a variety of enteroviruses. PROTAC EV-A71 Degrader-1 induces the degradation of EV-A71 3D polymerase through the ubiquitin-proteasome and autophagy-lysosome pathways, and blocks viral replication. PROTAC EV-A71 Degrader-1 protects infected mice from death, alleviates tissue damage, and exhibits safety profiles. PROTAC EV-A71 Degrader-1 can be used in the research of enterovirus infections.
(Pink: EV-A71 3D polymerase ligand (HY-19339); Blue: Ligands for E3 Ligase ligand (HY-W012479); Black: linker (HY-W105744)).

For research use only. We do not sell to patients.

Formula: C₃₉H₅₀N₆O₃S
Molecular Weight:682.92

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

PROTAC EV-A71 Degrader-1 Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Bioz

Biological Activity

Description

PROTAC EV-A71 Degrader-1 is a PROTAC degrader targeting EV-A71 3D polymerase, with broad-spectrum activity against a variety of enteroviruses. PROTAC EV-A71 Degrader-1 induces the degradation of EV-A71 3D polymerase through the ubiquitin-proteasome and autophagy-lysosome pathways, and blocks viral replication. PROTAC EV-A71 Degrader-1 protects infected mice from death, alleviates tissue damage, and exhibits safety profiles. PROTAC EV-A71 Degrader-1 can be used in the research of enterovirus infections^[1]. (Pink: EV-A71 3D polymerase ligand (HY-19339); Blue: Ligands for E3 Ligase ligand (HY-W012479); Black: linker (HY-W105744)).

All PROTACs Isoforms :

In Vitro

PROTAC EV-A71 Degrader-1 (compound N-6) (5-10 μM; 12-24 h) specifically degrades EV-A71 3D^pol in HEK293T cells and exhibits strong binding affinity (K_d = 8.08 nM)^[1].
PROTAC EV-A71 Degrader-1 (0.001-10 μM; 24-48 h) potently inhibits EV-A71 replication in RD cells, with an EC₅₀ of 0.149 μM, low cytotoxicity (CC₅₀ = 28.073 μM), and a high selectivity index of 188.409^[1].
PROTAC EV-A71 Degrader-1 (48 h) exhibits broad-spectrum, nanomolar anti-enterovirus activity against CV-A16, CV-B1, CV-A21, and EV-D68 in RD cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

RD cells
Concentration:

/
Incubation Time:

48 h
Result:

Achieved half-maximal effective concentration (EC50) values of 0.078 μM against CV-A16, 0.052 μM against CV-B1, 0.096 μM against CV-A21, and 0.123 μM against EV-D68.
Had EC90 values of 0.192 μM for CV-A16, 0.188 μM for CV-B1, 0.532 μM for CV-A21, and 0.324 μM for EV-D68.

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	C_max	AUC_0-t	AUC_0-∞	CL	F
Rat^[1]	3 mg/kg	i.v.	2.11 h	0.08 h	697 ng/mL	321 ng·h/mL	327 ng·h/mL	154 mL/min/kg	/
Rat^[1]	8 mg/kg	i.p.	12.1 h	6.67 h	14.2 ng/mL	222 ng·h/mL	212 ng·h/mL	629 mL/min/kg	24.3 %

In Vivo

PROTAC EV-A71 Degrader-1 (1-10 mg/kg; i.p.; daily; 4 days) protects 60% of EV-A71-infected neonatal KM mice from mortality, reduces virus-induced body weight loss and multiorgan histopathological damage, and exhibits a favorable safety profile^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Kunming (KM) mice (female, 7 days old, EV-A71 infection model via intraperitoneal injection of 1.0 × 10⁷ PFU mouse-adapted EV-A71 GZ-CII strain)^[1]
Dosage:

1 mg/kg (mortality protection, body weight loss alleviation, histopathology improvement); 10 mg/kg (safety assessment)
Administration:

i.p.; daily; 4 days
Result:

Protected 60% of infected mice from mortality.
Significantly alleviated virus-induced body weight loss.
Attenuated histopathological damage in liver, skeletal muscle, kidney, intestine, and brain (including reduced hepatic steatosis, myocyte necrosis, renal tubular atrophy, intestinal vacuolar degeneration, and neuronal pyknosis).
Caused no acute toxicity or body weight reduction in neonatal mice at 10 mg/kg dose.

Chemical Information

Molecular Weight 682.92
Formula C₃₉H₅₀N₆O₃S
SMILES

N[C@H](CC1=CNC2=C1C=CC=C2)C(NCCCCCCCCCC(NC3=CC=C(NC(NC(C4=CC=C(C(C)(C)C)C=C4)=O)=S)C=C3)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Fan T, et al. Identification of Novel Amino Acid-based PROTACs Exhibiting Broad-Spectrum Antiviral Activity Against Enteroviruses. J Med Chem. Published online April 8, 2026. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Get Quote In-stock